SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript

SOPHiA GENETICS SA (SOPH) reported Q2 2026 revenue of $23.3 million, up 27%, and an adjusted EBITDA loss of $8.8 million. Platform analysis volume rose 22% to 115,000 patient analyses. Management raised full-year revenue guidance to $94 million to $96 million and reaffirmed adjusted EBITDA loss of $29 million to $32 million, citing U.S. in-house testing demand and biopharma growth.

Original reporting
Published Aug 11, 2026, 5:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 11, 2026, 5:38 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
SOPHiA GENETICS (SOPH) Q2 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$SOPHBullishMed
01

Why it matters

Traders can update expectations for 2026 revenue and operating leverage based on raised full-year revenue guidance, Q2 margin dynamics, and reaffirmed adjusted EBITDA loss range.

02

Market read

The call provides concrete operating metrics (platform analyses, liquid biopsy customer adds, net dollar retention) plus updated financial guidance that can drive repricing.

03

What to watch

Patent litigation expenses (net $1.1M in Q2) and the mix shift toward lower-margin biopharma and services could continue to cap margin recovery even as volumes grow.

Relevance 8/10Novelty 7/10Timing: earnings call transcript, published Aug. 11 after Q2 results and guidance updates

Background

SOPHiA GENETICS held its Q2 2026 earnings call, detailing platform usage growth, liquid biopsy expansion, and progress toward EBITDA breakeven.

Company-level read

Ticker impact

$SOPHBullishMedium confidence
Context

SOPHiA reported Q2 revenue of $23.3M, raised full-year revenue guidance to $94M-$96M, and reaffirmed adjusted EBITDA loss guidance.

Expected impact

Bias toward near-term upside on guidance raise, tempered by continued adjusted EBITDA losses and gross margin decline.

Evidence & confidence

The article discloses multiple decision-relevant datapoints: raised revenue guidance, Q2 growth drivers (platform volume, liquid biopsy customers), and a reaffirmed EBITDA loss range despite margin softness.

Market effects

Signals continued demand strength in genomic diagnostics and liquid biopsy, with management emphasizing AI productivity and biopharma/CDx partnership momentum.

Highlights Asia Pacific revenue growth (31%) and volume expansion, which may support regional sentiment for precision oncology testing demand.

Reinforces the broader precision oncology ecosystem theme of scaling platform-based evidence generation and companion diagnostic collaborations.

Counterpoint

Despite the revenue beat and guidance raise, adjusted gross margin fell (72.1% vs 74.4%), and adjusted EBITDA loss guidance remains sizable, suggesting profitability progress may be slower than the revenue narrative implies.

Key entities

  • SOPHiA GENETICS SA

    Reported Q2 2026 results and guidance, including raised full-year revenue outlook and reaffirmed adjusted EBITDA loss range.

  • AstraZeneca

    Announced first two companion diagnostic programs with SOPHiA, described as SOPHiA's first CDx wins.

  • Memorial Sloan Kettering

    Memorandum of understanding for a joint venture to build an AI lab of the future in New York City.

  • Guardant Health

    Referenced in UK and France patent infringement defense costs tied to ongoing litigation.

Related articles

$SOPHMed

Sophia Genetics SA (SOPH) (Q3 2026) Earnings Call Highlights: Revenue Surges 25% with Strong

Sophia Genetics SA (SOPH) reported a 25% revenue surge in Q3 2026. CEO Ross Muken expects continued growth in 2027, driven by strong product momentum and a high backlog of customers. The company is investing in medical affairs to drive adoption and has secured notable biopharma collaborations, including with AstraZeneca. CFO George Cardoza emphasized profitability commitments and conservative guidance.

$SOPHMed

SOPHiA GENETICS S.A. Q3 2026 Earnings Call Summary

SOPHiA GENETICS reported Q3 2026 U.S. revenue growth of 41%, driven by improved reimbursement and lower sequencing costs. Liquid Biopsy volume surged over 100% YoY, led by the MSK-ACCESS product. The company projects full-year 2026 revenue at the upper end of $94M-$96M range, with 2027 revenue highly visible. Management expects positive adjusted EBITDA in H2 2027. The Unified Patent Court rejected Guardant Health's appeal, confirming no injunction against MSK-ACCESS.

$SOPHMed

SOPHiA (SOPH) Q3 2026 Earnings Call Transcript

SOPHiA (SOPH) reported Q3 2026 earnings, highlighting 19% growth in platform analyses to 118,000. U.S. revenue grew 41%, driven by new accounts and expanding services. Liquid Biopsy tests saw 100% year-on-year growth. The company also announced collaborations with BioPharma firms, including a top 10 company for bladder cancer research and AstraZeneca for companion diagnostics.

$SOPHMed

SOPHiA GENETICS Q3 Earnings Call Highlights

SOPHiA GENETICS reported 551 core genomics customers, up from 488 a year earlier, with 30 new logos signed. CFO George Cardoza highlighted net dollar retention at 118% and annualized revenue churn below 1%. Growth was seen in HemOnc, Rare Disorders, and Solid Tumor testing, with MSK-IMPACT Flex adoption driving Solid Tumor growth. Liquid biopsy volume doubled year-over-year.

$SOPHMed

SOPHiA GENETICS SA (SOPH): Financial results for Q3 2026

SOPHiA GENETICS SA (SOPH) furnished an SEC Form 6-K — earnings release. Exhibit 99.3 SOPHiA GENETICS Reports Third Quarter 2026 Results BOSTON, United States and ROLLE, Switzerland, November 3, 2026 — SOPHiA GENETICS (Nasdaq: SOPH), a global leader in AI-driven precision medicine, today reported financial results for the third quarter ended September